Medical management of patients with brain tumors

Current Opinion in Oncology

Volumn 14, Issue 3, 2002, Pages 299-307

  Wen, Patrick Y ^a,b   Marks, Peter W ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ATOVAQUONE; CARBAMAZEPINE; CLINDAMYCIN; CLONAZEPAM; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; DIETHYLENE GLYCOL MONOETHYL ETHER; ETIRACETAM; FOLINIC ACID; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PENTAMIDINE; PHENOBARBITAL; PHENYTOIN; PRIMAQUINE; PRIMIDONE; TIAGABINE; TOPIRAMATE; TRIMETREXATE; VALPROATE SEMISODIUM; ZONISAMIDE;

ANTICOAGULATION; BLEEDING; BONE MARROW SUPPRESSION; BRAIN EDEMA; BRAIN TUMOR; DIPLOPIA; DROWSINESS; HEART ARRHYTHMIA; HUMAN; HYPONATREMIA; INFECTION RISK; INFERIOR CAVA VEIN; LIVER TOXICITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEIZURE; THROMBOEMBOLISM; VERTIGO;

ANTICOAGULANTS; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BRAIN EDEMA; BRAIN NEOPLASMS; CEREBRAL HEMORRHAGE; HUMANS; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0036245549     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200205000-00008     Document Type: Review

References (126)

1. The diagnosis and management of patients with brain tumors
2. Medical management of cerebral metastases
3. The clinical study of gliomas
4. Brain tumors and chronic epilepsy
5. Epilepsy and brain tumors: Implications for treatment
6. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology
7. Seizure disorders in brain tumor patients
8. The pathogenesis of tumor associated epilepsy
9. Epilepsy
10. Efficacy, pharmacology, and adverse effects of antiepileptic drugs
11. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation
12. Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin
13. Stevens-Johnson syndrome in a patient receiving cranial irradiation and carbamazepine
14. Phenobarbital rheumatism in patients with brain tumor
15. Interference in the effect of dexamethasone by diphenylhydantoin
16. Phenytoin impairs the bioavailability of dexamethasone in neurologic and neurosurgical patients
17. Phenytoin-dexamethasone interaction: A previously unreported observation
18. Decreased phenytoin levels in patients receiving chemotherapy
19. Increased tenoposide clearance with concomitant anticonvulsant therapy
20. Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism
21. Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions
22. Increased 9-aminocampothecin dose requirements in patients on anticonvulsants
23. Phase I study of paclitaxel in patients with recurrent malignant gliomas: A North American Brain Tumor Consortium report
24. The effect of phenobarbital on the toxicity and tumoricidal activity of CCNU in a murine brain tumor model
25. Postoperative prophylactic anticonvulsant therapy in cerebral gliomas
26. The role of anticonvulsant mediciations in the management of patients with anaplastic gliomas
27. Influence of surgery and antiepileptic drugs on seizures symptomatic of brain tumors
28. The course of seizure disorders in patients with malignant gliomas
29. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis
30. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly-diagnosed brain tumors
31. Phenytoin and postoperative epilepsy
32. Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy
33. Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: A meta-analysis
34. Brain metastases from melanoma
35. Emerging molecular mechanisms of brain tumor edema
36. VEGF in brain tumors
37. Peritumoral edema
38. Intensive and postoperative care of intracranial tumors
39. Treatment of cerebral metastases from breast cancer with prednisone
40. Use of dexamethasone in the treatment of cerebral edema associated with brain tumors
41. Effect of dexamethasone in blood-brain barrier in the normal mouse
42. Cerebrospinal Fluid in Diseases of the Nervous System, edn 2
43. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor
44. Use of corticosteroids in neuro-oncology
45. Dose-effect relation of dexamethasone on Karnofsky performance in metastatic brain tumors: A randomized study of doses of 4, 8, and 16 milligrams per day
46. Use of glucocorticoids in neuro-oncology
47. Total care of the patient with a brain tumor
48. Steroid therapy and H2-receptor antagonists: Pharmacoeconomic implications
49. Is the steroid ulcer a myth?
50. Non-association of adrenocorticosteroid therapy and peptic ulcer
51. Association of adrenocorticosteroid therapy and peptic-ulcer disease
52. Adrenocorticosteroid administration and peptic ulcer: A critical analysis
53. Corticosteroids and peptic ulcer: Meta-analysis of adverse events during steroid therapy
54. Corticosteroid use and peptic ulcer disease: Role of anti-inflammatory drugs
55. The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids
56. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: A register-based cohort study
57. Steroids and peptic ulcer: An end to the controversy?
58. Steroid myopathy
59. Steroid-induced weakness in patients with primary brain tumors
60. Steroid myopathy in cancer patients
61. Insulin-like growth factor 1 inhibits glucocorticoid-induced glutamine synthetase activity in cultured L6 rat skeletal muscle cells
62. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi
63. Treatment and prophylaxis of Pneumocystis carinii pneumonia
64. New insights into transmission, diagnosis and drug treatment of Pneumocystis carinii pneumonia
65. Pneumocystis carinii pneumonia in patients with primary brain tumors
66. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors
67. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital
68. Pneumocystis pneumonia in brain tumor patients: Risk factors and clinical features
69. The growing problem of Pneumocystis carinii pneumonia among HIV negative brain tumor patients
70. Corticotrpin-releasing factor decreases vasogenic brain edema
71. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema
72. Phase II randomized dose-ranging trial of human corticotrophin releasing factor in symptomatic brain tumor patients
73. A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcoma
74. Thromboembolic phenomena in neurosurgical patients operated on for primary and metastatic brain tumors
75. Treatment of thromboembolic complcations in patients with brain tumors
76. Thromboembolism in brain tumors
77. The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence-based review
78. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: Risk analysis using medicare claims data
79. The incidence and significance of thromboembolic complications in patients with high grade gliomas
80. Incidence and risk of thromboembolism during treatment of high-grade gliomas: A prospective study
81. Thromboembolic phenomena in neurosurgical patients operated on for primary and metastatic brain tumors
82. The incidence and treatment of peripheral venous thombosis in patients with glioma
83. Postoperative venous thromboembolism and brain tumors: Part 1. Clinical profile
84. Thromboembolic disease in primary CNS lymphoma
85. Expression of tissue factor correlates with grade of malignancy in human glioma
86. Postoperative venous thromboembolism and brain tumors: Part III. Biochemical profile
87. Plasma fibrinolytic profile in patients with brain tumors
88. Hemostatic changes in patients with brain tumors
89. Pathogenetic mechanisms of thrombosis in malignancy
90. Update on tumor cell procoagulant factors
91. The thrombophilic state in cancer patients
92. Hemostatic changes during surgery for primary brain tumors
93. Prevention of thromboembolism (Sixth ACCP Consensus Conference on Antithrombotic Therapy)
94. Management of venous thromboembolism in cancer patients
95. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis
96. Enoxaparin plus compressive stockings compared with compressive stockings alone in the prevention of venous thromboembolism after elective neurosurgery
97. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery
98. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors
99. Low-molecular weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery
100. The diagnostic approach to acute venous thromboembolism. Clinical practice guideline
101. Antithrombotic therapy for venous thromboembolic disease
102. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism
103. D-dimer and impedence plethysmography in patients with suspected deep-vein thrombosis: Results of a management trial
104. The clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis
105. Use of a clinical model for safe management of patients with suspected pulmonary embolism
106. Diagnosis of pulmonary embolism with spiral computed tomography: Comparison with pulmonary angiography and scintigraphy
107. Intracranial hemorrhage caused by metastatic tumors
108. Complications of anticoagulant therapy in patients with known central nervous system lesions
109. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism
110. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors
111. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors: Anticoagulants or inferior vena cava filter?
112. Complications of therapy for veous thromboembolic disease in patients with brain tumors
113. Inferior vena cava filters in cancer patients: Indications and outcomes
114. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis: Prevention du Risque d'Emblie Pulmonaire par Interruption Cave Study Group
115. Therapy of venous thromboembolism in patients with brain metastases
116. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
117. Clinical uses of low-molecular-weight heparins
118. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
119. Treatment of venous thrombosis with intravenous unfractionated heparin administered in hospital as compared with subcutaneous low-molecular-weight heparin administered at home
120. Outpatient treatment of deep vein thrombosis: Translating clinical trials into practice
121. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
122. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
123. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial
124. Thromboembolism in patients with high-grade glioma